Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMODLN7)

Drug Name

IRX-2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]
Head and neck cancer	2D42	Phase 2	[1]
Squamous cell carcinoma	2B60-2D01	Phase 2	[2]
Breast cancer	2C60-2C65	Phase 1	[3]
leukaemia	2A60-2B33	Investigative	[4]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cytokine receptor unspecific (CRF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AD-452	DMMFLXN	Rheumatoid arthritis	FA20	Phase 2	[6]
JTE-607	DM1BQFY	Sepsis	1G40-1G41	Discontinued in Phase 2	[7]
VP-025	DM0HZBU	Alzheimer disease	8A20	Discontinued in Phase 1	[8]
VG-106	DMY0V6J	Solid tumour/cancer	2A00-2F9Z	Terminated	[9]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytokine receptor unspecific (CRF)	TTXM6JN	NOUNIPROTAC	Modulator	[5]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5	Clinical pipeline report, company report or official report of IRX Therapeutics.
6	Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9.
7	JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8.
8	List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Dis 2007;4:443-486.
9	WO patent application no. 2011,0955,45, Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same.